Abstract
IgM monoclonal antibodies directed against tumor cells which do not mediate antibody-dependent macrophage cytotoxicity (ADMC) even when they are cytotoxic in the presence of complement, have been shown to render macrophages tumoricidal when they carry an immunomodulating agent, i.e., muramyldipeptide (MDP).
This statement is based on experiments using two IgM monoclonal antibodies selected for their ability to bind L1210 leukemia cells (F2-10-23-IgM) and 3LL Lewis lung carcinoma cells (6B6-IgM) specifically, as shown by flow cytofluorometry analysis.
The MDP-IgM conjugates, containing 45 MDP molecules per IgM molecule, were prepared by allowing MDP-hydroxy-succinimide ester to react with IgM monoclonal antibodies.
The MDP-IgM conjugates are shown to bind to relevant tumor cells and to induce the activation of thioglycolate-elicited peritoneal mouse macrophages leading to 80% growth inhibition of target cells at optimum concentrations of bound MDP. These concentrations of bound MDP were 10 times lower than the concentration of free MDP, giving a maximum activation that is limited to 20% growth inhibition.
No macrophage activation was evidenced when tumor cells were incubated in the presence of irrelevant MDP-IgM conjugates and macrophages or when macrophages were preincubated in the presence of MDP-IgM conjugates and then incubated in the presence of relevant or irrelevant tumor cells but in the absence of the MDP-IgM conjugates.
The reported results are discussed with reference to the mechanism of activation of macrophage by muramyldipeptide and to the usefulness of such MDP-IgM conjugates as potential antitumor agents in cancer therapy.
Keywords: Macrophage Activation, Lewis Lung Carcinoma, Peritoneal Mouse Macrophage, Lewis Lung Carcinoma Cell, Muramyldipeptide
Abbreviations
- ADMC
antibody dependent macrophage mediated cytotoxicity
- F-GAM
fluoresceinylthiocarbamyl goat anti mouse antibody
- α-Man-BSA
α-mannopyranosyl-phenylthiocarbamyl bovine serum albumin containing some 25 mannose residues (neoglycoprotein)
- MDP
muramyldipeptide, 2-acetamido-3(2-0-d-lactyl-l-alanyl-d-glutamyl amine) glucopyranose
- MDP-F2-10-23-IgM
Murine monoclonal antibody specific of L1210 leukemia cells and substituted with 45 MDP molecules
- MDP—6B6-IgM
Murine monoclonal antibody specific of 3LL Lewis lung carcinoma cells and substituted with 45 MDP molecules
- MEM
minimal essential medium
- TDM
Trehalose-dimycolate
References
- 1.Adam A, Petit JF, Lefrancier P, Lederer E. Muramylpeptides. Mol Cell Biochem. 1981;41:27. doi: 10.1007/BF00225295. [DOI] [PubMed] [Google Scholar]
- 2.Baldwin RW, Pimm MV. Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targeting. Cancer Metastasis Review. 1983;2:89. doi: 10.1007/BF00046907. [DOI] [PubMed] [Google Scholar]
- 3.Chedid L, Morin A, Phillips N. Potential use of muramyl peptides in cancer therapy and prevention. In: Jeljaszewicz J, Pulverer G, Roszkowski W, editors. Bacteria and cancer. London: Academic Press; 1982. p. 49. [Google Scholar]
- 4.Diamond B, Bloom BR, Scharff MD. The Fc recptors of primary and cultured phagocytic cells studied with homogeneous antibodies. J Immunol. 1978;121:1329. [PubMed] [Google Scholar]
- 5.Fidler IJ, Sone S, Fogler WE, Barnes Z. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA. 1981;78:1680. doi: 10.1073/pnas.78.3.1680. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Fidler IJ, Barnes Y, Fogler WE, Kirsh R, Bugelski P, Poste G. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res. 1982;42:496. [PubMed] [Google Scholar]
- 7.Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci USA. 1982;79:4761. doi: 10.1073/pnas.79.15.4761. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Juy P, Chedid L. Comparison between macrophage activation and enhancement of non specific resistance to tumors by mycobacterial immunoadjuvants. Proc Natl Acad Sci USA. 1975;72:4105. doi: 10.1073/pnas.72.10.4105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Kennel SJ, Lankford T, Flynn KM. Therapy of a murine sarcoma using syngeneic monoclonal antibody. Cancer Res. 1983;43:2843. [PubMed] [Google Scholar]
- 10.Key HE. Macrophages in cancer metastases and their relevance to metastatic growth. Cancer Mestasis Reviews. 1983;2:75. doi: 10.1007/BF00046906. [DOI] [PubMed] [Google Scholar]
- 11.Kirch ME, Hammerling U. Immunotherapy of murine leukemias by monoclonal antibody. I. Effect of passively administered antibody on growth of transplanted tumor cells. J Immunol. 1981;127:805. [PubMed] [Google Scholar]
- 12.Levvy G.A, McAllan A. The N-acetylation and estimation of hexosamines. Biochem J. 1959;73:127. doi: 10.1042/bj0730127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Mantovani B. Phagocytosis of immune complexes mediated by IgM and C3 receptors by macrophages from mice treated with glycogen. J Immunol. 1981;126:127. [PubMed] [Google Scholar]
- 14.Mayo JC. Biologic characterization of the subcutaneously implanted Lewis lung tumor. Cancer Chemother Rep. 1972;3:325. [PubMed] [Google Scholar]
- 15.McLaughlin CA, Schwartzman SM, Horner BL, Jones GH, Moffat JG, Nestor JJ, Jr, Tegg D. Regression of tumors in guinea pigs after treatment with synthetic muramyl dipeptides and trehalose dimycolate. Science. 1980;208:415. doi: 10.1126/science.7189295. [DOI] [PubMed] [Google Scholar]
- 16.Merser C, Sinaÿ P, Adam A. Total synthesis and adjuvant activity bacterial peptidoglycan derivatives. Biochem Biophs Res Commun. 1975;66:1316. doi: 10.1016/0006-291x(75)90503-3. [DOI] [PubMed] [Google Scholar]
- 17.Midoux P, Roche AC, Monsigny M. Monoclonal antibodies (IgM) against a murine carcinoma, Lewis lung carcinoma (3LL):production and in vitro selectivity. Immunol Lett. 1984;8:131. doi: 10.1016/0165-2478(84)90065-8. [DOI] [PubMed] [Google Scholar]
- 18.Monsigny M, Kiéda C, Maillet T. Assay for proteolytic activity using a new fluorogenic substrate (peptidyl-3-amino-9-ethyl-carbazole): quantitative determination of lipopolysaccharide at the level of one picogram. EMBO J. 1982;73:127. doi: 10.1002/j.1460-2075.1982.tb01164.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Monsigny M, Roche AC, Bailly P. Tumoricidal activation of murine alveolar macrophages by muramyldipeptide substituted mannosylated serum albumin. Biochem Biophys Res Commun. 1984;121:579. doi: 10.1016/0006-291x(84)90221-3. [DOI] [PubMed] [Google Scholar]
- 20.Parant M, Parant F, Chedid L, Yapo A, Petit JF, Lederer E. Fate of the synthetic immunoadjuvant, muramyldipeptide (14C-labeled) in the mouse. Int J Immunopharmacol. 1979;1:35. doi: 10.1016/0192-0561(79)90028-6. [DOI] [PubMed] [Google Scholar]
- 21.Piessens WF, Churchill WH, Jr, David JR. Macrophages activated in vitro with lymphocyte mediators kill neoplastic but not normal cells. J Immunol. 1975;114:293. [PubMed] [Google Scholar]
- 22.Ralph P, Nakoinz I. Cell-mediated lysis of tumor targets directed by murine monoclonal antibodies of IgM and all IgG isotypes. J Immunol. 1983;131:1028. [PubMed] [Google Scholar]
- 23.Roche AC, Monsigny M. Monoclonal antibody (IgM) specific to mouse lymphoma cells (L1210): isolation and therapeutic properties. Cell Biol Int Rep. 1982;6:557. doi: 10.1016/0309-1651(82)90179-5. [DOI] [PubMed] [Google Scholar]
- 24.Schulz G, Bumol TF, Reisfeld RA. Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA. 1983;80:5407. doi: 10.1073/pnas.80.17.5407. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Seto M, Takahashi T, Nakamura S, Matsudaira Y, Nishizuka Y. In vivo antitumor effects of monoclonal antibodies with different immunoglobulin classes. Cancer Res. 1983;43:4768. [PubMed] [Google Scholar]
- 26.Sone S, Fidler IJ. In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyldipeptide encapsulated in liposomes. Cell Immunol. 1981;57:42. doi: 10.1016/0008-8749(81)90118-0. [DOI] [PubMed] [Google Scholar]
- 27.Steplewski Z, Lubeck MD, Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumor destroy human cancer cells. Science. 1983;221:865. doi: 10.1126/science.6879183. [DOI] [PubMed] [Google Scholar]